APP and Alzheimer disease: Using the APP/PS1 mouse model, a widely used platform for studying AD,36 we treated KDS12008, KDS12017, and KDS12025 (3 mg/kg/day (mpk), 16 times, intraperitoneal injection) to assess their ability to alleviate AD-like symptoms.